Boston Scientific Corp BSX generated Q1 revenues of $3.39 billion, beating the Wall Street estimate of $3.16 billion and the management growth estimate of 3%-5%.
Sales increased 12% Y/Y on a reported basis, 14.9% on an operational basis, and 14% on an organic basis.
The company achieved an adjusted EPS of $0.47, beating the consensus of $0.43 and management estimate of $0.42-$0.44.
Revenues from MedSurg increased 11% to $1.28 billion (13.4% organic), and the Cardiovascular segment generated $2.11 billion, +12.7% (14.4% organic).
The adjusted gross margin remained the same at around 70%, while the adjusted operating margin was 26%.
M&A Rumor: As a Bloomberg report last week, Boston Scientific was exploring a possible acquisition of Shockwave Medical Inc SWAV.
Outlook: Boston Scientific estimates Q2 FY3 adjusted EPS of $0.48-$0.50 versus the consensus of $0.48.
The company expects Q2 sales growth of approximately 6.5%-8.5% (7-9% organic).
For FY23, Boston Scientific sees the FY23 adjusted EPS of $1.90-$1.96 compared to the prior guidance of $1.86-$1.93 versus the Wall Street Estimate of $1.91.
The company estimates FY23 sales growth of approximately 8.5%-10.5% on a reported basis compared to 5%-7% expected earlier and approximately 8%-10% organically vs. 6%-8% expected earlier.
Price Action: BSX shares are up 1.90 at $50.14 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.